[go: up one dir, main page]

PE20090165A1 - Composicion farmaceutica a base de telmisartan - Google Patents

Composicion farmaceutica a base de telmisartan

Info

Publication number
PE20090165A1
PE20090165A1 PE2008000465A PE2008000465A PE20090165A1 PE 20090165 A1 PE20090165 A1 PE 20090165A1 PE 2008000465 A PE2008000465 A PE 2008000465A PE 2008000465 A PE2008000465 A PE 2008000465A PE 20090165 A1 PE20090165 A1 PE 20090165A1
Authority
PE
Peru
Prior art keywords
telmisartan
pharmaceutical composition
composition based
disgregants
methylbenzimidazole
Prior art date
Application number
PE2008000465A
Other languages
English (en)
Inventor
Ruediger Thomas
Frieder Ulrich Maerz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38179677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20090165A1 publication Critical patent/PE20090165A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN COMPRIMIDO QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II EN FORMA AMORFA TAL COMO TELMISARTAN (ACIDO 4'-[2-n-PROPIL-4-METIL-6-(1-METILBENCIMIDAZOL-2-IL)-BENCIMIDAZOL-1-ILMETIL]-BIFENIL-2-CARBOXILICO), SORBITOL Y UN AGENTE BASICO TAL COMO HIDROXIDOS DE METAL ALCALINO, AMINOACIDOS BASICOS Y MEGLUMINA. EL TELMISARTAN ESTA PRESENTE EN UNA CANTIDAD DE ENTRE 10 MG Y 160 MG Y TIENE UN TAMANO DE PARTICULA MENOR DE 80 uM. DICHO COMPRIMIDO COMPRENDE EXCIPIENTES TALES COMO AGLUTINANTES, DISGREGANTES, SOLUBILIZANTES, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION
PE2008000465A 2007-03-14 2008-03-12 Composicion farmaceutica a base de telmisartan PE20090165A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104157A EP1970053A1 (en) 2007-03-14 2007-03-14 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
PE20090165A1 true PE20090165A1 (es) 2009-03-31

Family

ID=38179677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000465A PE20090165A1 (es) 2007-03-14 2008-03-12 Composicion farmaceutica a base de telmisartan

Country Status (35)

Country Link
US (1) US20100143465A1 (es)
EP (2) EP1970053A1 (es)
JP (1) JP5742045B2 (es)
KR (1) KR101503674B1 (es)
CN (1) CN101641084B (es)
AR (1) AR065726A1 (es)
AT (1) ATE493119T1 (es)
AU (1) AU2008225754B2 (es)
BR (1) BRPI0808797A2 (es)
CA (1) CA2680608C (es)
CL (1) CL2008000733A1 (es)
CO (1) CO6220927A2 (es)
CY (1) CY1111350T1 (es)
DE (1) DE602008004217D1 (es)
DK (1) DK2120884T3 (es)
EA (1) EA018574B1 (es)
EC (1) ECSP099629A (es)
ES (1) ES2358770T3 (es)
HR (1) HRP20110012T1 (es)
IL (1) IL200125A (es)
MA (1) MA31251B1 (es)
MX (1) MX2009009201A (es)
MY (1) MY145089A (es)
NZ (1) NZ580185A (es)
PE (1) PE20090165A1 (es)
PL (1) PL2120884T3 (es)
PT (1) PT2120884E (es)
RS (1) RS51584B (es)
SI (1) SI2120884T1 (es)
TN (1) TN2009000371A1 (es)
TW (1) TWI406678B (es)
UA (1) UA96982C2 (es)
UY (1) UY30961A1 (es)
WO (1) WO2008110599A1 (es)
ZA (1) ZA200905224B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2009058950A2 (en) * 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2009135646A2 (en) 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
CZ301070B6 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
GB0822171D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Temisartan formulations
ES2598490T3 (es) 2009-05-20 2017-01-27 Boehringer Ingelheim Vetmedica Gmbh Disolución farmacéutica bebible de telmisartán
EP2844067A4 (en) * 2012-03-19 2015-11-25 Althera Life Sciences Llc ORAL TABLET FORMULATION OF ROSUV ASTATIN WITH IMMEDIATE RELEASE AND METOMETINE WITH DELAYED RELEASE
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
JP6096328B2 (ja) * 2014-02-10 2017-03-15 富士フイルム株式会社 口腔内崩壊錠
BE1021954B1 (nl) * 2014-06-05 2016-01-28 Syral Belgium Nv Samenstelling van sorbitol met lage friabiliteit
FR3023128B1 (fr) 2014-07-01 2017-11-10 Roquette Freres Nouvelle composition edulcorante
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
CN106420739A (zh) * 2016-10-31 2017-02-22 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
CN106800537B (zh) * 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN109316451B (zh) * 2017-07-31 2022-07-01 武汉朗来科技发展有限公司 治疗高血压和相关疾病的口服固体制剂
SG11202010792TA (en) 2018-05-02 2020-11-27 Ferring Bv Improved pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245170A1 (de) * 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
FR2787110B1 (fr) * 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent et son procede de preparation
EA007614B1 (ru) * 2002-01-16 2006-12-29 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Двухслойная фармацевтическая таблетка и способ ее получения
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
HRP20140212T1 (hr) * 2004-11-05 2014-04-11 Boehringer Ingelheim International Gmbh Dvoslojna tableta koja sadrži telmisartan i amlodipin
JP2008524136A (ja) * 2004-12-17 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング テルミサルタンとヒドロクロロチアジドを含む併用療法
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy

Also Published As

Publication number Publication date
JP2010530844A (ja) 2010-09-16
MA31251B1 (fr) 2010-03-01
TWI406678B (zh) 2013-09-01
ZA200905224B (en) 2010-04-28
EP1970053A1 (en) 2008-09-17
EP2120884A1 (en) 2009-11-25
AU2008225754B2 (en) 2013-04-04
UA96982C2 (ru) 2011-12-26
BRPI0808797A2 (pt) 2013-01-15
US20100143465A1 (en) 2010-06-10
AR065726A1 (es) 2009-06-24
CN101641084B (zh) 2013-04-10
IL200125A0 (en) 2010-04-15
HRP20110012T1 (hr) 2011-02-28
KR20090119998A (ko) 2009-11-23
DK2120884T3 (da) 2011-02-07
HK1140692A1 (en) 2010-10-22
AU2008225754A1 (en) 2008-09-18
UY30961A1 (es) 2008-10-31
EA018574B1 (ru) 2013-09-30
RS51584B (sr) 2011-08-31
CL2008000733A1 (es) 2008-07-04
TW200900095A (en) 2009-01-01
CO6220927A2 (es) 2010-11-19
JP5742045B2 (ja) 2015-07-01
IL200125A (en) 2012-01-31
EA200901169A1 (ru) 2010-04-30
CA2680608A1 (en) 2008-09-18
PL2120884T3 (pl) 2011-05-31
ECSP099629A (es) 2009-10-30
EP2120884B1 (en) 2010-12-29
MY145089A (en) 2011-12-30
NZ580185A (en) 2011-11-25
WO2008110599A1 (en) 2008-09-18
CA2680608C (en) 2015-06-16
KR101503674B1 (ko) 2015-03-18
SI2120884T1 (sl) 2011-04-29
MX2009009201A (es) 2009-09-08
CN101641084A (zh) 2010-02-03
CY1111350T1 (el) 2015-08-05
ES2358770T3 (es) 2011-05-13
ATE493119T1 (de) 2011-01-15
TN2009000371A1 (fr) 2010-12-31
DE602008004217D1 (de) 2011-02-10
PT2120884E (pt) 2011-02-10

Similar Documents

Publication Publication Date Title
PE20090165A1 (es) Composicion farmaceutica a base de telmisartan
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
AR084620A1 (es) Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
ES2487271T3 (es) Formulaciones de dosificación sólidas inhibidoras de DPP-IV
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
CL2009000598A1 (es) Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis.
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
CL2012000626A1 (es) Composición farmacéutica oral de liberación sostenida, que comprende dentro de una forma de dosificación única, (i) una matriz hidrofílica, (ii) una cantidad terapéuticamente eficaz de un compuesto no opioide que contiene amina, (iii) una sal de un fármaco aine, y (iv) opcionalmente un surfactante aniónico.
PE20142368A1 (es) Formas de dosificacion del tapentadol novedosas y potentes
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
CO6400186A2 (es) Tabletas de acetato de ulipristal
MX349106B (es) Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
MY147641A (en) Fast release paracetamol tablets
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
IN2015DN00637A (es)
TN2009000358A1 (en) Pharmaceutical compositions comprising a calcilytic agent
PT2389070E (pt) Formulações desintegráveis de carbonato de lantânio
AR086789A1 (es) Comprimido masticable de ibuprofeno
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed